Five things for pharma marketers to know: Monday, June 6, 2016
1. Researchers say some multiple-myeloma patients should be prescribed multiple drugs, which raises concerns about costs. Adding Johnson & Johnson's Darzalex to an older two-drug cocktail increases efficacy but could cost at least $180,000 for one year of treatment. (WSJ)
2. Kite Pharma and Juno Therapeutics, which are both developing CAR-T therapies, say their experimental cancer drugs may be approved in 2017. The therapies, which are mainly being tested in blood cancers, harness the immune system's T cells to fight cancers. (Reuters)
3. The FDA approved Allergan's Byvalson, a hypertension treatment. The therapy, which combines Bystolic and valsartan, is expected to be available in the second half of the year.
4. A biosimilar version of Roche's Herceptin is comparable in safety and effectiveness to the brand-name drug, according to data presented at ASCO. Mylan is developing the breast-cancer biosimilar, Myl-1401O. (WSJ)
5. Martin Shkreli is facing new charges. Prosecutors allege that he used employees and consultants to conceal control of his stock while he was serving as CEO of Retrophin. (Bloomberg)